Our data provide insight into how the relatively safe simvastatin may also be beneficial in the management of tumor growth and cancers by specifically regulating the levels of the angiogenic VEGFR2 and subsequently reducing VEGF mediated signaling in endothelial cells. This evidence concerns the gene VEGFA and cancer.